Cardiac and Pulmonary Assessment in Egyptian Patients With Rheumatoid Arthritis

Not yet recruiting

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT05938244
• Lead Sponsor: Assiut University

Brief Summary

To determine cardiac and pulmonary involvement in RA patients To assess the correlation between cardiopulmonary findings in RA patients with disease activity.

To compare between diaphragmatic ultrasonography and PFT i.e. spirometry as a screening tool for restrictive pulmonary disorders.

To assess correlation between anterior chest wall ultrasound and pulmonary function test in RA patients.

Detailed Description

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with systemic manifestations targeting primarily synovial joints and periarticular tissues, with a 1-3% prevalence, it is the most prevalent form of inflammatory arthritis.(1,2) Although synovitis is the pathological hallmark of RA, numerous extra-articular symptoms and comorbidities are probably present.(3) Cardiovascular and pulmonary system diseases are the two main causes of death in RA patients, and their symptoms are the most serious.(2,3) Patients with RA have a 50% greater risk of CV mortality and a two-fold increased risk of myocardial infarction, which is the most common cause of death in this population. (4) Echocardiographic examination is considered a good predictive tool for some cardiac conditions with early findings while no clinical signs is yet found on these patients. (5) The second major cause of death in patients with RA is respiratory disease, which occurs in 30-40% of patients.(6) Sometimes the disease is silent until it has lung complications, which come before joint problems. RA may affect the lung interstitium, airways, and pleurae, while pulmonary vascular involvement is less frequent.(7) Diaphragmatic ultrasound can be used to determine the prevalence of interstitial lung disease involvement in RA as a restrictive disorder. The association between pulmonary function tests (PFTs), potential risk factors, and clinical correlation must be calculated.(8)(9) Anterior chest wall (ACW ) joints undergo joint changes and can be involved along the course of RA yet seems to be underestimated(1) Ultrasonography of ACW can detect those changes even before being clinically evident (10)

Study Timeline

• Study First Submitted: 2023-06-25
• Status Verified: 2023-07
• Study First Submitted QC: 2023-07-03
• Last Update Submitted: 2023-07-03
• Study First Posted: 2023-07-10
• Last Update Posted: 2023-07-10
• Study Start: 2023-08
• Primary Completion: 2023-12
• Study Completion: 2024-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Any patient satisfying 2010 ACR/ EULAR RA classification criteria

Exclusion Criteria

• Patients with definite diagnosis for any other systemic autoimmune disorders

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine cardiac and pulmonary involvement in RA patients	1 year	By using spirometry, echocardiography

Secondary Outcome Measures

Name	Time	Method
To assess correlation between anterior chest wall ultrasound and pulmonary function test in RA patients	1 year	Anterior chest wall musculoskeletal ultrasonography
To assess the correlation between cardiopulmonary findings in RA patients with disease activity	1 year	Using DAS28 as a measurement tool for activity
To compare between diaphragmatic ultrasonography and PFT i.e. spirometry as a screening tool for restrictive pulmonary disorders	1 year	Using diaphragmatic ultrasonography and pulmonary function test